Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

Figure 1

Relapse-free survival curves for patients classified by clinical and genetic characteristics. (A) Patients who achieved pCR and those who did not, (B) patients with HER2 copy numbers ≤ 2.0 and those with HER2 copy numbers >2.0 in the tumors, (C) patients with wild-type HER2 mRNA < 400 and those with wild-type HER2 mRNA ≥ 400 in the tumors, (D) patients with Δ16HER2 mRNA < 2.4% and those with Δ16HER2 mRNA ≥ 2.4% in the tumors, (E) patients with gain of FOXA1 and those with a normal copy or UPD of FOXA1 in the tumors, (F) patients with gain of CDH3 and those with a normal copy, loss, or UPD of CDH3 in the tumors.

Back to article page